BUCHANG PHARMA(SH:603858)2023-04-27 16:00Financial Performance - The company's operating revenue for 2022 was approximately CNY 14.95 billion, a decrease of 5.15% compared to 2021[16]. - The net profit attributable to shareholders for 2022 was approximately -CNY 1.66 billion, representing a decline of 228.51% year-over-year[16]. - The basic earnings per share for 2022 was -CNY 1.4980, a decrease of 228.52% compared to the previous year[17]. - The company reported a net cash flow from operating activities of approximately CNY 2.76 billion, an increase of 108.68% from 2021[16]. - The total assets at the end of 2022 were approximately CNY 21.95 billion, down 8.48% from the previous year[16]. - The company's key products, including Naoxin capsules and Danhong injection, generated a total revenue of CNY 9,481 million in 2022, reflecting their established market presence[23]. - The company reported a total revenue of CNY 10,107,277,375.36 in the cardiovascular sector, reflecting a year-over-year decrease of 9.43%[75]. - The gross margin for the cardiovascular sector was 78.73%, which decreased by 3.55% compared to the previous year[75]. Dividend and Shareholder Returns - The company plans to distribute a cash dividend of RMB 9.60 per 10 shares, totaling RMB 1,061,800,939.20, based on a total share capital of 1,106,042,645 shares as of December 31, 2022[4]. - The board has approved a dividend payout of 0.2 CNY per share, reflecting a commitment to returning value to shareholders[114]. Audit and Compliance - The company has received a standard unqualified audit report from the accounting firm Xin Yong Zhong He[3]. - The board of directors has ensured the authenticity, accuracy, and completeness of the annual report[2]. - The company has not faced any situations where more than half of the directors cannot guarantee the authenticity of the annual report[5]. - The company has not reported any significant changes in accounting policies that would impact its financial status or operational results[178]. - The company has not faced any issues related to non-standard audit opinions from its accounting firm[176]. Research and Development - The company applied for 51 new patents and successfully obtained 56 patents, including 20 invention patents, indicating a strong focus on innovation and R&D[24]. - The company is actively developing 12 biological products targeting major diseases, with some already in clinical phases I or III, showcasing its commitment to advancing in the biopharmaceutical sector[24]. - The company invested CNY 512 million in R&D in 2022, a decrease of 19.25% year-over-year, representing 3.43% of total revenue[76]. - The company has 215 products under research as of December 2022, including 11 traditional Chinese medicines, 182 chemical drugs, 17 biological drugs, and 5 medical devices[96]. Market Strategy and Expansion - The company is focusing on expanding its market presence in the cardiovascular medication sector, which is expected to grow due to the increasing prevalence of related diseases[31]. - The company plans to invest in establishing several subsidiaries, including Bichang Health Industry and Changsha Zhongce Biotechnology, to expand its market presence and enhance competitiveness[24]. - The company is exploring partnerships and collaborations to enhance its research capabilities and expedite the development of new therapies[78]. - The company plans to enhance its production capacity by expanding its production base to meet the growing demand for its products[97]. Environmental and Social Responsibility - The company invested 1,053.80 million RMB in environmental protection during the reporting period[147]. - The company has established a comprehensive internal control system, with no significant deficiencies reported during the period[143]. - Total charitable contributions amounted to CNY 11.6945 million, with CNY 4.014 million in cash donations and CNY 7.6805 million in material donations[166]. - The company has not engaged in poverty alleviation or rural revitalization efforts during the reporting period[168]. Financial Management and Investments - The company has entrusted financial management with a total amount of 4,136,170,000.00 RMB, with an outstanding balance of 400,000,000.00 RMB[191]. - The company reported a total of 1.1 billion RMB in structured deposit products, with an average interest rate of 2.85% across various banks[193]. - The company has diversified its investment strategy by incorporating structured deposits with embedded financial derivatives, improving overall yield[193]. - The company aims to maintain a conservative investment approach while seeking opportunities for growth in the financial market[193]. Governance and Management - The total pre-tax remuneration for the board members during the reporting period amounted to CNY 1,517.65 million[108]. - The company has a total of 13 board members, with 5 independent directors[107]. - The company has undergone changes in its executive team, with some members having left during the reporting period[107]. - The remuneration for directors and senior management is determined based on performance evaluation systems and business innovation capabilities[118].